

=> d his

(FILE 'HOME' ENTERED AT 05:37:12 ON 28 NOV 2007)

FILE 'REGISTRY' ENTERED AT 05:37:17 ON 28 NOV 2007

L1 STRUCTURE UPLOADED

L2 8 S L1

L3 267 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 05:38:00 ON 28 NOV 2007

L4 7 S L3

L5 0 S US200!-551933/ASPPS

L6 6 S US200!-551933/APPS

L7 1 S L4 AND L6


L8 6 S L4 NOT L7

FILE 'REGISTRY' ENTERED AT 05:38:34 ON 28 NOV 2007

=> d l1

L1 HAS NO ANSWERS

L1 STR





Cb 1 Hy 2

G1 C,O,S,N

G2 [@1] , [@2]

Structure attributes must be viewed using STN Express query preparation.



chain nodes :

19 20 26

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 15 16

ring bonds :

1-2 1-5 2-3 3-4 4-5 4-6 5-9 6-7 7-8 7-10 8-9 8-13 10-11 10-15 10-16 11-12
12-13

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 4-6 5-9 6-7 7-8 7-10 8-9 8-13 10-11 10-15 10-16 11-12
12-13

isolated ring systems :

containing 1 :

G1:C,O,S,N

G2:[*1],[*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 15:CLASS 16:CLASS 19:Atom 20:Atom 26:CLASS 27:CLASS

Generic attributes :

19:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic
20:

Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : Exactly 1
Type of Ring System : Monocyclic

Element Count :

Node 19: Limited
C,C6

Node 20: Limited
C,C5
N,N1


L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:927012 CAPLUS
 DN 141:395547
 TI Preparation of selective spirocyclic glucocorticoid receptor modulators
 IN Ali, Amjad; Balkovec, James M.; Beresis, Richard; Colletti, Steven L.;
 Graham, Donald W.; Patel, Gool F.; Smith, Cameron J.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 201 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004093805	A2	20041104	WO 2004-US12102	20040419
	WO 2004093805	A3	20051208		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004232301	A1	20041104	AU 2004-232301	20040419
	CA 2522946	A1	20041104	CA 2004-2522946	20040419
	EP 1617806	A2	20060125	EP 2004-760029	20040419
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1809347	A	20060726	CN 2004-80017051	20040419
	JP 2006524251	T	20061026	JP 2006-513140	20040419
	US 2006217563	A1	20060928	US 2005-551933	20051004 <--
	IN 2005DN04611	A	20070928	IN 2005-DN4611	20051010
PRAI	US 2003-464784P	P	20030423		
	WO 2004-US12102	W	20040419		
OS	MARPAT 141:395547				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Ring A = carbocyclyl or heterocyclyl; m = 0-3; n = 0-2; R1 = (un)substituted-alkyl, -alkenyl, -alkynyl, -cycloalkyl, etc.; R2 and R3 independently = H, halo, alkyl, aryl, etc.; R4 = OH, CO2H, (un)substituted-alkyl, -Ph, etc.] , as well as their pharmaceutically acceptable salts or hydrates thereof, are prepared and disclosed as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Thus, e.g., II was prepared via spirocyclization of III (preparation given) with Et α -bromomethyl acrylate. In human glucocorticoid receptor assays, I demonstrated a range of GR affinity with IC50 values between 10 μ M and 1 nM. Pharmaceutical compns. and methods of use are also included.

ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS ON STN
 2005:461153 CAPLUS Full-text
 143:125827
 TI Novel ketal ligands for the glucocorticoid receptor: in vitro and in vivo activity
 AU Smith, Cameron J.; Ali, Amjad; Balkovec, James M.; Graham, Donald M.; Hammond, Milton L.; Patel, Gool P.; Rouen, Gregory P.; Smith, Scott K.; Tate, James R.; Einstein, Monica; Ge, Lan; Harris, Georgianna S.; Kelly, Theresa M.; Mazur, Paul; Thompson, Chris M.; Wang, Chuanlin P.; Williamson, Joanne M.; Miller, Douglas K.; Pandit, Shilpa; Santoro, Joseph C.; Sitalani, Ayesha; Yamin, Ting-ting D.; O'Neill, Edward A.; Zaller, Dennis M.; Carballo-Jane, Ester; Forrest, Michael J.; Luell, Silvio
 CS Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ, 07065, USA
 SO Bioorganic & Medicinal Chemistry Letters (2005), 15(11), 2926-2931
 CODEN: BMCLER; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 143:125827
 GI




AB A novel series of selective ligands for the human glucocorticoid receptor is described. Structure-activity studies focused on variation of B-ring size, ketal ring size, and ketal substitution. These analogs were found to be potent and selective ligands for GR and have partial agonist profiles in functional assays for transactivation (TAT, GS) and transrepression (IL-6). Of these compds., three were evaluated further in a mouse LPS-induced TNF- α secretion model. Compound (1) had an ED₅₀ of 14.1 mg/kg compared with 0.5 mg/kg for prednisolone in the same assay.

IT 786709-06-3
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
 (novel ketal ligands for glucocorticoid receptor and in vitro and in vivo activity)
 RN 786708-06-3 CAPLUS
 CN Spiro[cyclopent[5H]indazole-5,2'-(1,3)dioxolane], 4',5'-diethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (4'R,4aS,5'R)- (CA INDEX NAME)

Absolute stereochemistry.


IT 614762-99-1P 786707-55-9P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (novel ketal ligands for glucocorticoid receptor and in vitro and in vivo activity)
 RN 614762-99-1 CAPLUS
 CN Spiro[5H-benz[f]indazole-5,2'-(1,3)dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 786707-55-9 CAPLUS
 CN Spiro[cyclopent[5H]indazole-5,2'-(1,3)dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.




IT 786707-70-8
 RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
 (novel ketal ligands for glucocorticoid receptor and in vitro and in vivo activity)
 RN 786707-70-8 CAPLUS
 CN Spiro[5H-benz[f]indazole-5,2'-(1,3)dioxolane], 4',5'-diethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (CA INDEX NAME)

Absolute stereochemistry.





IT 786708-45-0P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (novel ketal ligands for glucocorticoid receptor and in vitro and in vivo activity)
 RN 786708-45-0 CAPLUS
 CN Spiro[cyclopent[5H]indazole-5,2'-(1,3)dioxolane], 4',5'-diethyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, stereoisomer (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 786708-33-6
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (novel ketal ligands for glucocorticoid receptor and in vitro and in vivo activity)
 RN 786708-33-6 CAPLUS
 CN Spiro[cyclopent[5H]indazole-5,2'-(1,3)dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,6'-trimethyl-, (4'S,4aS,6'S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 786707-65-1P 786707-67-3P 786707-68-4P
 SS8371-49-0P SS9271-51-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (novel ketal ligands for glucocorticoid receptor and in vitro and in vivo activity)
 RN 786707-65-1 CAPLUS
 CN Spiro[5H-benz[f]indazole-5,2'-(1,3)dioxolane], 4',5'-diethyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 786707-67-3 CAPLUS
 CN Spiro[5H-benz[f]indazole-5,2'-(1,3)dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-dipropyl-, (4'R,4aS,5'R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 786707-68-4 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-dibutyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (CA INDEX NAME)

Absolute stereochemistry.





RN 858371-49-0 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-
1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-di-2-propenyl-, (4'R,4aS,5'R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 858371-51-4 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-
4,4a,6,7-tetrahydro-4a-methyl-4',5'-di-2-propenyl-, (4'R,4aS,5'R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 786708-14-3 CAPLUS
CN Spiro[cyclopent[*f*]indazole-5(1*H*),2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'*R*,4'*S*,4a*S*)- (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-15-4 CAPLUS
CN Spiro[cyclopent[*f*]indazole-5(1*H*),2'-[1,3]dioxolane], 4'-ethenyl-1-{4-fluorophenyl}-4,4a,6,7-tetrahydro-4a-methyl-, (2*S*,4*S*,4a*S*)- (CA INDEX NAME)

Absolute stereochemistry.




RN 786708-16-5 CAPLUS
CN Spiro[cyclopent[*f*]indazole-5(1*H*),2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2*R*,4*R*,4*as*)- (CA INDEX NAME)

Absolute stereochemistry.

IT 796707-63-9 786708-10-9 786708-11-0
786708-14-3 786708-15-4 786708-16-5
786709-17-6 786709-18-7 786709-19-8
786708-20-1 786708-21-2 796702-14-3
786705-36-9 787619-93-6 787620-09-5
787620-02-4 787620-09-1 787630-10-4
R53711-54-7 859371-55-8 859371-57-0
RE: PAC (Pharmacological activity), THU (Therapeutic use); BIOL
(Biological activity); USES (Uses)
(novel metal ligands for glucocorticoid receptor and in vitro and in
vivo activity)


RN 786707-63-9 CAPLUS
 CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-
 1,4,4a,6,7,8-hexahydro-4a,5'-trimethyl-, {4'R,4aS,5'R}- (CA INDEX
 NAME)

Absolute stereochemistry.




RN 786708-10-9 CAPLUS
CN Spiro[cyclopent[*f*]indazole-5(1*H*),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-
4,4a,6,7-tetrahydro-4a-methyl-4',5'-diphenyl-, (4'*R*,4*a*S,5'*R*)- (CA INDEX
NAME)

Absolute stereochemistry.




RN 786708-11-0 CAPLUS
CN Spiro[cyclopent[*f*]indazole-5(1*H*),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-
4,4a,6,7-tetrahydro-4',5'-bis(methoxymethyl)-4a-methyl-, (4*R*,4*aS*,5*R*)-
(CA INDEX NAME)

Absolute stereochemistry.




RN 786708-17-6 CAPLUS
CN Spiro[cyclopent(f)indazole-5(1H),2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'S,4'R,4aS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 786708-18-7 CAPLUS
CN Spiro[cyclopent({}indazole-5(1H), 2'-{1,3}dioxolane), 1-(4-fluorophenyl)-
4,4a,6,7-tetrahydro-4a-methyl-4'-phenyl-, (2'S,4'R,4aS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 786708-19-8 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H), 2'-[1,3]dioxolane], 1-(4-fluorophenyl)-
4,4a,6,7-tetrahydro-4a-methyl-4'-phenyl-, (2'R,4'R,4aS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 786708-20-1 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4'-phenyl-, (2'R,4'S,4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-21-2 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4'-phenyl-, (2'S,4'S,4aS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-34-7 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a,5',5''-trimethyl-, (4aS)- (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 787620-02-4 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,5'-trimethyl-, (4'R,4aS,5'R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 787620-09-1 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,6',6''-trimethyl-, (4'R,4aS,6'R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 787620-10-4 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,6',6''-trimethyl-, (4'R,4aS,6'S)- (CA INDEX NAME)




RN 786708-36-9 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,6',6''-tetramethyl-, (2'S,4aS,6'R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 787619-93-6 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-diphenyl-, (4'R,4aS,5'R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 787620-00-2 CAPLUS
CN Spiro[cyclopent[f]indazole-5,2'-[1,3]dioxane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4',4a,6',6''-trimethyl-, (4'R,4aS,6'R)- (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 858371-54-7 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a-dimethyl-, (2'S,4'R,4aS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 858371-55-8 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,6',6''-pentamethyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 858371-57-0 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,6',6''-pentamethyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.




IT 796708-00-7P 796708-30-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (novel ketal ligands for glucocorticoid receptor and in vitro and in vivo activity)
 RN 796708-00-7 CAPLUS
 CN Spiro[5H-benz[f]indazole-5,2'-(1,3)dioxane], 1-(4-fluorophenyl)-, 1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 796708-30-3 CAPLUS
 CN Spiro[cyclopent[f]indazole-5(1H),2'-(1,3)dioxane], 1-(4-fluorophenyl)-, 4,4a,6,7-tetrahydro-4a-methyl-, (4aS)- (CA INDEX NAME)


Absolute stereochemistry.



AB Title compds. represented by the formula I [wherein J = NR1, CR1R2; K = NR3, CR3R4; L = NR5, CR5R6; X = hydroxy, alkoxy, carbamoyl, etc.; R1-R6 = independently H, halo, (cyclo)alkyl, etc.; R7 = H, hydroxy, alkoxy, aryl, etc.; R8 = (cyclo)alkyl, alkenyl, alkynyl, etc.; R9, R10 = independently halo, hydroxy, alkyl, alkenyl, alkoxy; n = 0-2; and pharmaceutically acceptable salts or hydrates thereof] were prepared as selective non-steroidal glucocorticoid receptor modulators. For example, II was given in a multi-step synthesis starting from 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-cyclopent[f]indazol-5(1H)-one reacting with phenylethynylmagnesium bromide. I showed affinity of glucocorticoid receptor with IC50 values between 10 μM and 1 nM. Thus, I and their pharmaceutical compns. are useful for the treatment of a variety of autoimmune and inflammatory diseases or conditions.

IT 614762-99-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of cyclopent[f]indazol-5-yl and benz[f]indazol-5-yl derivs. as selective non-steroidal glucocorticoid receptor modulators)
 RN 614762-99-1 CAPLUS
 CN Spiro[5H-benz[f]indazole-5,2'-(1,3)dioxane], 1-(4-fluorophenyl)-, 1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



Intermediate

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STM
 2004-220010 CAPLUS Full-text

DN 140:287380
 TI Preparation of octahydro-2-H-naphtho[1,2-f]indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators for the treatment of autoimmune and inflammatory conditions
 IN Ali, Amjad; Aster, Susan D.; Balkovec, James M.; Graham, Donald W.; Hunt, Julianne A.; Kallashi, Florida; Sinclair, Peter J.; Tata, James R.; Taylor, Gayle E.; Goulet, Joung L.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 170 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
MO 2004026248	A2	20040401	MO 2003-US29494	20030917

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STM
 2004-240124 CAPLUS Full-text
 DN 141:260743
 TI Preparation of cyclopent[f]indazole and benz[f]indazole derivatives selective non-steroidal glucocorticoid receptor modulators
 IN Ali, Amjad; Beres, Richard; Colletti, Steven L.; Graham, Donald W.; Tata, James R.; Thompson, Christopher F.
 PA Merck & Co. Inc., USA
 SO PCT Int. Appl., 105 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
MO 2004075840	A2	20040910	MO 2004-US5199	20040220
MO 2004075840	A3	20050203		
MO 2004075840	A9	20050804		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NA, NI, NG, NH, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BM, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2004216182 A1 20040910 AU 2004-216182 20040220
 CA 2516684 A1 20040910 CA 2004-2516684 20040220
 EP 1599201 A2 20051130 EP 2004-713398 20040220
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2006518752 T 20060817 JP 2006-503780 20040220
 US 2006074120 A1 20060406 US 2005-544899 20050808
 PRAI US 2003-450811P P 20030225
 MO 2004-US5199 W 20040220
 OS MARPAT 141:260743
 GI



II

WO 2004026248 A3 20040715
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NA, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2499150 A1 20040401 CA 2003-2499150 20030917
 AU 2003270783 A1 20040408 AU 2003-270783 20030917
 EP 1542996 A2 20050622 EP 2003-752495 20030917
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2006503107 T 20060817 JP 2004-568945 20030917
 US 2005245588 A1 20051103 US 2005-527615 20050311
 PRAI US 2002-412231P P 20020920
 US 2003-476079P P 20030605
 WO 2003-US29494 W 20030917
 OS MARPAT 140:287380
 GI



II


AB Octahydro-2-H-naphtho[1,2-f]indole-4-carboxamide derivs. I (X = CO, NHCO, CONH, NH, CH2NH; R1, R2 = H, alkyl, alkenyl, cycloalkyl, alkoxy, aryl; R3 = alkyl, alkoxy, acid, halogen substituted alkyl; R4 = alkyl, alkenyl, cycloalkoxy, alkoxy, aryl) were prepared as selective glucocorticoid receptor modulators for the treatment of autoimmune and inflammatory conditions. Thus, (S)-Wieland-Miescher ketone was protected as the ketal using p-toluene sulfonic acid and ethylene glycol and then treated with Et formate to give the hydroxymethylene ketal derivative. The hydroxymethylene was dissolved in acetic acid and reacted with p-fluorophenyl hydrazine hydrochloride to give II. The ketal of II was converted to the ketone using 6N HCl, and the resulting ketone transformed into the triflate. The triflate was treated with tributylvinyl tin and PPh3 to give the corresponding coupling product. Treatment with ethyl-4,4,4-trifluorocrotonate followed by dropwise addition of BCl3 gave the target I (R1 = CF3, R2, R3 = H, X = CO, R4 = OEt),.

IT 614762-99-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of octahydronaphthoindole-4-carboxamide deriva. as selective glucocorticoid receptor modulators for the treatment of autoimmune and inflammatory conditions)

RN 614762-99-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (CA INDEX NAME)


Absolute stereochemistry.



intermediate

ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STM
2004:267662 CAPLUS [Full-text](#)

TI Novel N-Arylpyrazolo[3,2-c]-Based Ligands for the Glucocorticoid Receptor: Receptor Binding and in Vivo Activity
AU Ali, Amjad; Thompson, Christopher P.; Balkovec, James M.; Graham, Donald W.; Hammond, Milton L.; Quraishi, Nazia; Tata, James R.; Einstein, Monica; Ge, Lan; Harris, Georgianna; Kelly, Terri M.; Mazur, Paul; Pandit, Shilpa; Santoro, Joseph; Sitlani, Ayesha; Wang, Chuanlin; Williamson, Joanne; Miller, Douglas K.; Thompson, Chris M.; Zaller, Dennis M.; Forrest, Michael J.; Carballo-Jane, Ester; Luelz, Silvi
CS Departments of Medicinal Chemistry, Metabolic Disorders Immunology and Pharmacology, Merck Research Laboratories, Rahway, NJ, 07065, USA
SO Journal of Medicinal Chemistry (2004), 47(10), 2441-2452
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 141:7063
GI




I

AB A novel series of selective ligands for the human glucocorticoid receptor (hGR) are described. Preliminary structure-activity relationships were focused on substitution at C-1 and indicated a preference for 3-, 4-, and 5-substituted aromatic and benzylic groups. The resulting analogs, e.g., 1 [R = OH, R1 = 3,4,5-MeO(F2)C6H2, CH2C6H4F-4], exhibited excellent affinity for hGR (IC50 1.9 nM and 2.8 nM, resp.) and an interesting partial agonist profile in functional assays of transactivation (tyrosine aminotransferase, TAT, and glutamine synthetase, GS) and transrepression (IL-6). The most potent compds. were 1 [R = 4-FC6H4, 2-thienyl, R1 = OH]. These candidates showed highly efficacious IL-6 inhibition vs. dexamethasone. 1 [R = 2-thienyl, R1 = OH] was evaluated in vivo in the mouse LPS challenge model and showed an ED50 = 4.0 mg/kg, compared to 0.5 mg/kg for prednisolone in the same assay.

IT 614762-99-1P
RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and glucocorticoid receptor binding of (aryl(hydroxy)methyl)naphthopyrazoles)
RN 614762-99-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



intermediate

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STM
2003:836773 CAPLUS [Full-text](#)

TI Preparation of 1H-Benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
AU Ali, Amjad; Balkovec, James M.; Graham, Donald W.; Thompson, Christopher P.; Quraishi, Nazia
IN Merck & Co., Inc., USA
SO PCT Int. Appl., 233 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003086294	A2	20031023	WO 2003-US10867	20030408
WO 2003086294	A3	20040715		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH.

PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, SH, TD, TO
CA 2481320 A1 20031023 CA 2003-2481320 20030408
AU 2003221706 A1 20031027 AU 2003-221706 20030408
EP 1496892 A2 20050119 EP 2003-718285 20030408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2005528385 T 20050922 JP 2003-583721 20030408
US 2005256315 A1 20051117 US 2005-506897 20050428
US 7282591 B2 20071016
PRAI US 2002-371948P P 20020411
WO 2003-US10867 W 20030408
OS MARPAT 139:323524
GI




II

AB Benzindazoles I [n = 0-2; J, K, L = (un)substituted CH2, NH; X = bond, CO, (un)substituted NH, NHCO, 1,1-cyclopropanediyl; R1, R2 = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, aryl, aralkyl, heterocyclic, aryloxy, aroyloxy, OH; R3 = H, (un)substituted OH, alkyl, aryl, aralkyl; Y = H, (un)substituted OH, SH, S(O)H, SO2H, CH2, NH2, SO2NH2, CO2H, NO2, acyl, CN, halogen; and the carbocyclic rings may be further substituted] were prepared for use as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions (no data). Thus, Wieland-Wiescher ketone was ketalized, hydroxymethylated, cyclized with 4-FC6H4NHNH2, deprotected, treated with Ph3P-CH2OMe Cl-, and subjected to Grignard reaction with 4-FC6H4MgCl to give the benzindazole II.
IT 614762-99-1P 614763-03-4P
RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1H-benzo[f]indazol-5-yl deriva. as selective glucocorticoid


receptor modulators)
RN 614762-99-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 614763-23-4 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-oxirane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STM
2003:590999 CAPLUS [Full-text](#)


TI Preparation of non-steroidal ligands for the glucocorticoid receptor
AU Scanlan, Thomas S.; Shah, Nilesh
IN The Regents of the University of California, USA
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003061651	A1	20030731	WO 2003-US1997	20030122

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,

- no clue about actual
context is of something
that would be
from comp
- no motivation for this
only
intermediate


UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RM: GH, GM, KE, LS, MN, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SH, TD, TG
 CA 2473886 A1 20030731 CA 2003-2473886 20030122
 US 2003176478 A1 20030918 US 2003-350260 20030122
 US 6831093 B2 20041214
 EP 1467730 A1 20041020 EP 2003-710722 20030122
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2005523254 T 20050804 JP 2003-561595 20030122
 US 2005054700 A1 20050310 US 2004-972250 20041022
 PRAI US 2002-351484P P 20020122
 US 2002-373757P P 20020417
 US 2003-350260 A3 20030122
 WO 2003-US1997 W 20030122
 OS MARPAT 139:149523
 GI



11

AB Naphthoheterocycles I [A, B, D = C, N, O, S, at least one of A, B, and D being N, O, or S; W = C, O, N, S; R1 = H, (un)substituted alkyl, acyl, NH2, CO2H, aralkyl, CONH2, heterocyclic, CN, halogen; R2, R3, R5, R6, R6', R7 = H, (un)substituted alkyl, acyl, alkoxy, NH2, sulfonyl, sulfinyl, SH, CO2H, aralkyl, CONH2, heterocyclic, OH, CN, halogen; R2', R3', R5', R7', R8 = absent or H, (un)substituted alkyl, acyl, NH2, alkoxy, sulfonyl, sulfinyl, SH, aralkyl, CONH2, heterocyclic, CN, halogen; R4 = absent or H, (un)substituted alkyl, acyl, NH2, CO2H, aralkyl, CONH2, heterocyclic, CN, halogen; R9 = absent or H, (un)substituted alkyl, alkoxy, NH2, CO2H, CN, halogen, O, S, OH; R10 = absent or H, (un)substituted alkyl, acyl, CO2H, aralkyl, aryl, cycloalkyl, heterocyclic; R2R10 = atoms required to form a ring; R11, R12 = H, (un)substituted alkyl, acyl, NH2, alkoxy, sulfonyl, sulfinyl, SH, aryl, aralkyl, CONH2, heterocyclic, OH, CN, halogen, O, S] were prepared as non-steroidal ligands for the glucocorticoid receptor. They are useful for treating or preventing diseases (e.g., obesity, diabetes, depression, neurodegeneration of an inflammatory disease) associated with glucocorticoid binding to the glucocorticoid receptor. Thus, Wieland-Miescher ketone was

converted to its 5-ethyleneketal, hydroxymethylenated, and cyclized with 4-PC6H4NNH2 to give the benzindazolone II which had IC50 of 436 nM in a glucocorticoid receptor binding test.
 IT 571203-14-0P
 RL: RCT (Reactant), SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 RN 571203-14-0 CAPLUS
 CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

	SINCE FILE	TOTAL
→ log hold		
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	34.92	212.17
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	-5.46	-5.46

SESSION WILL BE HELD FOR 120 MINUTES
 STN INTERNATIONAL SESSION SUSPENDED AT 05:39:23 ON 28 NOV 2007